Access cutting-edge graft-versus-host disease treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access graft-versus-host disease specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related graft-versus-host disease treatment provided free
This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cells attack the healthy tissue of the body. The most common symptoms are skin rash, jaundice, nausea, vomiting, and/or diarrhea. The standard treatment for GVHD is high dose steroids such as prednisone or methylprednisolone, which suppresses the donor cells, but sometimes there can be either no respon
Sponsor: John Levine
Check if you qualify for this graft-versus-host disease clinical trial in New York, NY
If you're searching for graft-versus-host disease treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced graft-versus-host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.